1. Home
  2. IROQ vs GANX Comparison

IROQ vs GANX Comparison

Compare IROQ & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IROQ
  • GANX
  • Stock Information
  • Founded
  • IROQ 1883
  • GANX 2017
  • Country
  • IROQ United States
  • GANX United States
  • Employees
  • IROQ N/A
  • GANX N/A
  • Industry
  • IROQ Savings Institutions
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • IROQ Finance
  • GANX Health Care
  • Exchange
  • IROQ Nasdaq
  • GANX Nasdaq
  • Market Cap
  • IROQ 82.2M
  • GANX 69.0M
  • IPO Year
  • IROQ 2011
  • GANX 2021
  • Fundamental
  • Price
  • IROQ $25.60
  • GANX $1.66
  • Analyst Decision
  • IROQ
  • GANX Strong Buy
  • Analyst Count
  • IROQ 0
  • GANX 5
  • Target Price
  • IROQ N/A
  • GANX $8.20
  • AVG Volume (30 Days)
  • IROQ 1.6K
  • GANX 614.3K
  • Earning Date
  • IROQ 11-03-2025
  • GANX 11-13-2025
  • Dividend Yield
  • IROQ 1.56%
  • GANX N/A
  • EPS Growth
  • IROQ 139.63
  • GANX N/A
  • EPS
  • IROQ 1.37
  • GANX N/A
  • Revenue
  • IROQ $26,459,000.00
  • GANX N/A
  • Revenue This Year
  • IROQ N/A
  • GANX N/A
  • Revenue Next Year
  • IROQ N/A
  • GANX N/A
  • P/E Ratio
  • IROQ $18.74
  • GANX N/A
  • Revenue Growth
  • IROQ 19.82
  • GANX N/A
  • 52 Week Low
  • IROQ $18.36
  • GANX $1.36
  • 52 Week High
  • IROQ $25.97
  • GANX $3.19
  • Technical
  • Relative Strength Index (RSI)
  • IROQ 63.23
  • GANX 44.47
  • Support Level
  • IROQ $25.32
  • GANX $1.55
  • Resistance Level
  • IROQ $25.50
  • GANX $1.78
  • Average True Range (ATR)
  • IROQ 0.25
  • GANX 0.14
  • MACD
  • IROQ 0.01
  • GANX -0.03
  • Stochastic Oscillator
  • IROQ 81.68
  • GANX 21.15

About IROQ IF Bancorp Inc.

IF Bancorp Inc is a holding company. It is mainly engaged in the business of directing, planning, and coordinating the business activities of Iroquois Federal. The company with the association take deposits from the general public and invest those deposits together with funds generated from operations and borrowings in various loans such as multi-family residential and mortgage loans, commercial real estate loans, home equity lines of credit, consumer loans, others and also a variety of deposit accounts and alternative delivery channels.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: